Tem Group has been acquired by Instrumentation Laboratory
The shareholders of Tem Group (TEM) have sold the company to Instrumentation Laboratory (IL). Financial details have not been disclosed.
TEM is a global leader in in-vitro diagnostic (IVD) testing for Patient Blood Management (PBM) with their flagship ROTEM testing systems. With a direct sales force in seven markets, including the USA, TEM has consistently achieved above market growth in the PBM market. In hospital trauma and surgical patients with clinically significant bleeding, ROTEM whole blood analyzers provide a rapid differential diagnosis of coagulopathies. This supports targeted transfusion and coagulation factor concentrate therapy and, as a result, is key to PBM programs. PBM is a multi-disciplinary, evidence-based medical concept, optimizing a patient’s own blood volume, minimizing blood loss and thereby significantly reducing or avoiding blood transfusion.
IL, founded in 1959 and based in Bedford, Massachusetts, is a worldwide developer, manufacturer and distributor of in-vitro diagnostic instruments, related reagents and controls for use primarily in hospitals and independent clinical laboratories. The company’s product lines include critical care systems, hemostasis systems and information management systems. IL is an integral part of the Werfen family of companies which distributes its products by a direct sales force in North America and Werfen organizations around the globe.
"A passion for innovation, leading systems and extensive knowledge in PBM, make TEM a perfect complement to our focus, commitment, and leadership in hemostasis and critical care IVD," said Ramon Benet, CEO at IL. "IL and our global Werfen organizations are ideally positioned to maximize the potential of the ROTEM product line, which intersects our existing business and presents synergies in our core competencies and customer call points. Most importantly, ROTEM systems share the same ultimate benefit of all our products, to help customers reduce overall hospital costs, while improving patient care."
Oaklins' team in Switzerland advised the seller in this transaction.
Talk to the deal team
Related deals
MEDIK Hospital Design Group has been acquired by STERIS
The private shareholders of MEDIK Hospital Design Group have sold their shares to STERIS plc. Together, MEDIK and STERIS will expand their offerings for hospitals and ambulatory surgery centers worldwide. MEDIK’s solutions ideally complement STERIS’ existing portfolio, enabling the combined group to strengthen its position as a leading provider of turnkey room solutions in surgical and IPT environments. The MEDIK management team will actively support the next phase of growth.
Learn morebioXXmed AG has sold Rancoderm GmbH to Rose Investment- und Beteiligungs AG
Rancoderm GmbH has been acquired by Rose Investment- und Beteiligungs AG to secure the funding required for the final development and market approval of its medical device DermaPro. The acquisition will enable Rancoderm to bring DermaPro to market readiness and launch it as a certified medical product for broad distribution.
Learn moreSLT has been acquired by Indutrade
SLT S.r.l. has been acquired by Indutrade AB and will be integrated into the group’s life science business area. The transaction is Indutrade’s fifth acquisition in 2025 and is expected to have a marginally positive impact on the group’s earnings per share.
Learn more